계정 가입
이미 존재한 계정
가입을 클릭하여 코인타임의 <a class="underline" href="#term-of-service">서비스 약관</a> 과 a class="underline" href="#privacy-policy">개인정보 보호 정책</a> . 에 동의함.
email 로 로그인
email 로 가입
사용자 이메일
수신함을 확인하세요
중의 링크를 통해 로그인 하세요
중의 링크를 통해 가입 하세요
ATAI Life Sciences
company
About
ATAI Life Sciences develops innovative mental health treatments that address significant unmet medical needs.
- 101 - 250
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $93M
- Industries
- Biotechnology,Health Care,Life Science,Therapeutics
- Founded date
- Jan 1, 2018
- Number Of Employee
- 101 - 250
- Operating Status
- Active
- Investor Type
- CVC
ATAI is a global biotech company builder that leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering from mental health disorders. The company is committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space.ATAI Life Sciences was founded in 2018 and is based in Munich, Bayern, Germany.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
3
$425M
ATAI Life Sciences has raised a total of
$425M
in funding over 2 rounds. Their latest funding was raised on
Aug 15, 2022 from a Post-IPO Debt round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 15, 2022 | Post-IPO Debt | $175M | 1 |
Hercules Capital
|
— | Detail |
| Mar 3, 2021 | Series D | $157M | 2 | — | — | Detail |
| Nov 24, 2020 | Series C | $93M | 1 | — | — | Detail |
Investments
Number of Investments
Number of Lead Investments
5
4
ATAI Life Sciences has made 5 investments. Their most recent investment was on
Jan 9, 2023, when IntelGenX raised $3M.
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Jan 9, 2023
IntelGenX
|
Post-IPO Debt | $3M | Biotechnology | Yes |
|
Feb 1, 2022
IntelGenX
|
Post-IPO Debt | $3M | Biotechnology | Yes |
|
Mar 15, 2021
IntelGenX
|
Post-IPO Equity | $12.34M | Biotechnology | Yes |
|
Mar 15, 2021
IntelGenX
|
Post-IPO Debt | $2M | Biotechnology | Yes |
|
Apr 24, 2019
Innoplexus
|
Series C | — | Analytics | — |
Investors
Number of Lead Investors
Number of Investors
1
3
ATAI Life Sciences is funded by 3 investors.
Hercules Capital
and Korify Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Hercules Capital
|
Yes | Post-IPO Debt |
Korify Capital
|
— | Series D |
Gaingels
|
— | Series D |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
